Skip to main content

Esperion Therapeutics, Inc.

ESPRDelisted Jul 13, 2026
Industry
Pharmaceutical Preparations
SEC CIK
0001434868

Esperion Therapeutics, Inc. was delisted on Jul 13, 2026; its insiders filed their last Form 4 on Jul 13, 2026; 191 institutions reported holding it in 13F filings for Q2 2026, worth $646.8M in total; Soros Fund Management was the only superinvestor holding it.

Q3 2023 vs. Q2 2023

How the institutions holding Esperion Therapeutics, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of ESPR: Q2 2023 compared with Q3 2023
MeasureQ2 2023Of which not filed for Q3 2023Q3 2023Change
Holders12411230
Shares74.4M10077.3M+2.90M (+3.9%)
Value$103.6M$139$75.9M−$27.7M (−26.7%)

1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (21)

Institutions that held Esperion Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to ESPR in Q3 2023
InstitutionSharesValue% of portfolio
Parallel Advisors, LLC478,000$468.4K0.02%
AQR Capital Management LLC202,985$198.9K0.00%
Virtu Financial LLC181,597$178.0K0.02%
Graham Capital Management, L.P.157,747$154.6K0.00%
Acadian Asset Management LLC136,346$131.0K0.00%
Cubist Systematic Strategies, LLC112,802$110.5K0.00%
Jacob Asset Management of New York LLC60,000$58.8K0.08%
Charles Schwab Investment Management Inc57,991$56.8K0.00%
Two Sigma Securities, LLC36,678$35.9K0.00%
Prudential Financial Inc33,260$32.6K0.00%
Sawtooth Solutions, LLC30,502$29.9K0.00%
Bleakley Financial Group, LLC30,502$29.9K0.00%
Squarepoint Ops LLC27,969$27.4K0.00%
Chicago Partners Investment Group LLC29,499$23.5K0.00%
Bayesian Capital Management, LP17,600$17.2K0.00%
GTS Securities LLC14,127$13.8K0.00%
Warberg Asset Management LLC13,000$12.8K0.00%
Summit Financial, LLC11,887$11.6K0.00%
WT Wealth Management10,100$9.90K0.00%
DHJJ Financial Advisors, Ltd.1,500$1.47K0.00%
Creative Planning100$980.00%

Sold out (21)

Institutions that held Esperion Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Not filed for Q3 2023 yet (1)

Institutions that held Esperion Therapeutics, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ESPR in Q2 2023 that haven't filed for Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Kistler-Tiffany Companies, LLC100$139